ResultsĪ considerable proportion of gliomas exhibited a significantly increased level of serum autoantibody relative FAP level. Additionally, the investigation encompassed the correlation between postoperative tumor burden, as assessed through volumetric analysis, and the relative FAP level of serum autoantibodies. To validate the presence of FAP expression in tumors, immunohistochemistry was conducted on four gliomas employing a FAP-specific antibody. A series of FAP tests were conducted on 33 cases of malignant gliomas in order to ascertain their efficacy in monitoring the progression of the disease in relation to imaging observations. The correlation between preoperative serum autoantibody relative FAP levels and postoperative pathology, including molecular pathology was investigated. We adopted enzyme-linked immunosorbent assay (ELISA) technique to quantify the relative FAP level of serum autoantibodies in a cohort of 87 gliomas. This study seeks to evaluate the feasibility of glioma detection through the utilization of a serum FAP marker. Glioma-circulating biomarkers have not yet been used in clinical practice. The role of fibroblast activation protein (FAP) in gliomas has been demonstrated to facilitate tumor progression. Detecting tumor progression of glioma continues to pose a formidable challenge.
